JPMorgan Chase & Co. raised its position in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 107.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 205,943 shares of the company's stock after acquiring an additional 106,823 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.16% of Organogenesis worth $589,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Captrust Financial Advisors purchased a new position in Organogenesis during the 3rd quarter worth approximately $36,000. Intech Investment Management LLC purchased a new position in shares of Organogenesis during the third quarter worth approximately $43,000. Pallas Capital Advisors LLC increased its holdings in shares of Organogenesis by 70.8% in the 3rd quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company's stock valued at $63,000 after acquiring an additional 9,048 shares during the period. Mackenzie Financial Corp raised its position in Organogenesis by 46.1% in the 2nd quarter. Mackenzie Financial Corp now owns 24,328 shares of the company's stock valued at $68,000 after purchasing an additional 7,678 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Organogenesis in the 3rd quarter valued at $72,000. Institutional investors and hedge funds own 49.57% of the company's stock.
Organogenesis Stock Performance
Organogenesis stock traded down $0.08 during midday trading on Friday, hitting $3.69. 571,224 shares of the company's stock were exchanged, compared to its average volume of 536,821. The firm's 50 day simple moving average is $3.45 and its 200 day simple moving average is $3.14. Organogenesis Holdings Inc. has a 12-month low of $2.16 and a 12-month high of $4.57. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The stock has a market cap of $463.57 million, a price-to-earnings ratio of -61.75 and a beta of 1.77.
Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million for the quarter, compared to analysts' expectations of $109.59 million. During the same quarter in the previous year, the firm posted $0.02 EPS. Equities research analysts predict that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.
Insider Transactions at Organogenesis
In related news, CEO Gary S. Gillheeney sold 41,052 shares of the firm's stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $3.52, for a total value of $144,503.04. Following the completion of the sale, the chief executive officer now owns 3,359,726 shares in the company, valued at $11,826,235.52. This trade represents a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 278,116 shares of company stock worth $991,190 over the last 90 days. 36.90% of the stock is currently owned by insiders.
Organogenesis Company Profile
(
Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Further Reading
Before you consider Organogenesis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.
While Organogenesis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
